OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press100510.17650/1818-8346-2025-20-1-65-72NEW DIRECTIONS, DIAGNOSTIC OPPORTUNITIES, AND TREATMENT ADVANCESНОВЫЕ НАПРАВЛЕНИЯ, ВОЗМОЖНОСТИ ДИАГНОСТИКИ И УСПЕХИ ЛЕЧЕНИЯDiffusion-weighted magnetic resonance imaging as an alternative to positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose in patients with lymphomas: a literature review and clinical observationsДиффузионно-взвешенная магнитно-резонансная томография как альтернатива позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, с 18F-фтордезоксиглюкозой у пациентов с лимфомами. Обзор литературы и клинические наблюденияhttps://orcid.org/0000-0003-1329-8689AlekseevS. A.АлексеевС. А.
Russian Federation

Sergey Anatolievich Alekseev

105094; 3 Gospital’naya Ploshchad’; Moscow

Сергей Анатольевич Алексеев

105094; Госпитальная пл., 3; Москва

alxvsrge@gmail.comhttps://orcid.org/0000-0002-8008-9660TroyanV. N.ТроянВ. Н.
Russian Federation

105094; 3 Gospital’naya Ploshchad’; Moscow

105094; Госпитальная пл., 3; Москва

https://orcid.org/0000-0002-1309-7265RukavitsynO. A.РукавицынО. А.
Russian Federation

105094; 3 Gospital’naya Ploshchad’; Moscow

105094; Госпитальная пл., 3; Москва

https://orcid.org/0000-0002-9885-5829TrefilovA. A.ТрефиловА. А.
Russian Federation

105094; 3 Gospital’naya Ploshchad’; Moscow

105094; Госпитальная пл., 3; Москва

Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of RussiaФГБУ «Главный военный клинический госпиталь им. акад. Н. Н. Бурденко» Минобороны России1903202520165722003202520032025https://oncohematology.abvpress.ru/ongm/article/view/1005

   Diffusion‑weighted magnetic resonance imaging may provide an alternative to traditional methods such as computed tomography and positron emission tomography / computed tomography with 18F‑fluorodeoxyglucose. The article analyzes not only the advantages of the method, but also the disadvantages and pitfalls that a diagnostician has to face. data from own studies on the use of whole‑body diffusion‑weighted magnetic resonance imaging in patients with lymphomas are presented.

   Диффузионно‑взвешенная магнитно‑резонансная томография может стать альтернативой традиционным методам, таким как компьютерная томография и позитронно‑эмиссионная томография, совмещенная с компьютерной томографией, с 18F‑фтордезоксиглюкозой. В статье проанализированы не только преимущества метода, но и недостатки и «подводные камни», с которыми приходится сталкиваться врачу‑диагносту. Представлены данные собственных исследований о применении диффузионно‑взвешенной магнитно‑резонансной томографии всего тела у пациентов с лимфомами.

diffusion‑weighted magnetic resonance imagingcomputed tomographyfluorodeoxyglucosenon‑Hodgkin’s lymphomapositron emission tomographymeasured diffusion coefficientдиффузионно‑взвешенная магнитно‑резонансная томографиякомпьютерная томографияфтор‑дезоксиглюкозанеходжскинская лимфомапозитронно‑эмиссионная томографияизмеряемый коэффициент диффузииThe work was performed without external fundingРабота выполнена без спонсорской поддержкиRukavitsyn O.A., Troyan V.N., Kryukov E.V. et al. Radiologic diagnostics for blood system diseases. Moscow: GEOTAR­Media, 2021. 224 p. (In Russ.). DOI: 10.33029/9704­6333­8­DIA­2021­1­224Рукавицын О.А., Троян В.Н., Крюков Е.В. и др. Лучевая диагностика при заболеваниях системы крови. М.: ГЭОТАР­ Медиа, 2021. 224 с. DOI: 10.33029/9704­6333­8­DIA­2021­1­224Rukavitsyn O.A., Udal’eva V.Yu., Ageeva T.A. et al. Hematology : National Guide. 2nd edn, revised and supplemented. Moscow: GEOTAR-­Media, 2024. 916 p. (In Russ.). DOI: 10.33029/9704­8188­2­GEM­2024­1­916Рукавицын О.А., Удальева В.Ю., Агеева Т.А. и др. Гематология : национальное руководство. 2-­е изд., перераб. и доп. М.: ГЭОТАР­-Медиа, 2024. 916 с. DOI: 10.33029/9704­8188­2­GEM­2024­1­916Glockner J.F., Hu H.H., Stanley D.W. et al. Parallel MR imaging: a user’s guide. Radiographics 2005;25(5):1279–97. DOI: 10.1148/rg.255045202Ballon D., Watts R., Dyke J.P. et al. Imaging therapeutic response in human bone marrow using rapid whole­body MRI. Magn Reson Med 2004;52(6):1234–8. DOI: 10.1002/mrm.20291De Bazelaire C., de Kerviler E. From multislice CT to whole­body biomarker imaging in lymphoma patients. Eur Radiol 2011;21(3):555–8. DOI: 10.1007/s00330­010­2035­9Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31(11):1860–1.Cheson B.D. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4(1):5. DOI: 10.3978/j.issn.2304­3865.2014.11.03Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non­Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059–68. DOI: 10.1200/JCO.2013.54.8800Brenner D., Elliston C., Hall E. et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001;176(2):289–96. DOI: 10.2214/ajr.176.2.1760289Mathews J.D., Forsythe A.V., Brady Z. et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 2013;346:f2360. DOI: 10.1136/bmj.f2360Jerusalem G., Beguin Y., Najjar F. et al. Positron emission tomography (PET) with 18F­fluorodeoxyglucose (18F­FDG) for the staging of low­grade non­Hodgkin’s lymphoma (NHL). Ann Oncol 2001;12(6):825–30. DOI: 10.1023/a:1011169332265Townsend D.W. Multimodality imaging of structure and function. Phys Med Biol 2008;53(4):R1–39. DOI: 10.1088/0031­9155/53/4/R01Kwee T.C., Takahara T., Ochiai R. et al. Whole­body diffusion-weighted magnetic resonance imaging. Eur J Radiol 2009;70(3):409–17. DOI: 10.1016/j.ejrad.2009.03.054Darge K., Jaramillo D., Siegel M.J. Whole­body MRI in children: current status and future applications. Eur J Radiol 2008;68(2): 289–98. DOI: 10.1016/j.ejrad.2008.05.018Wong F.C., Kim E.E. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009;70(2):205–11. DOI: 10.1016/j.ejrad.2009.01.049Lin C., Luciani A., Itti E. et al. Whole­body diffusion­weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B­cell lymphoma. Eur Radiol 2010;20(8):2027–38. DOI: 10.1007/s00330­010­1758­yDudeck O., Zeile M., Pink D. et al. Diffusion­weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft­tissue sarcomas. J Magn Reson Imaging 2008;27(5):1109–13. DOI: 10.1002/jmri.21358Wu X., Kellokumpu­Lehtinen P.L., Pertovaara H. et al. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B­cell lymphoma – a pilot study: comparison with 2­-deoxy­2-­fluoro-­D­glucose­positron emission tomography/computed tomography. NMR Biomed 2011;24(10):1181–90. DOI: 10.1002/nbm.1689Chen Y., Zhong J., Wu H., Chen N. The clinical application of whole­body diffusion­weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging 2012;30(2):165–70. DOI: 10.1016/j.mri.2011.09.019Gu J., Chan T., Zhang J. et al. Whole­body diffusion­weighted imaging: the added value to whole­body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197(3):W384–91. DOI: 10.2214/AJR.10.5692Stéphane V., Samuel B., Vincent D. et al. Comparison of PET­CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013;82(11):2011–7. DOI: 10.1016/j.ejrad.2013.05.042Van Ufford H.M., Kwee T.C., Beek F.J. et al. Newly diagnosed lymphoma: initial results with whole­body T1-­weighted, STIR, and diffusion­weighted MRI compared with 18F­FDG PET/CT. AJR Am J Roentgenol 2011;196(3):662–9. DOI: 10.2214/AJR.10.4743Padhani A.R., Koh D.M., Collins D.J. Whole­body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700–18. DOI: 10.1148/radiol.11110474Le Bihan D., Poupon C., Amadon A., Lethimonnier F. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging 2006;24(3):478–88. DOI: 10.1002/jmri.20683Nasu K., Kuroki Y., Sekiguchi R. et al. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med 2006;24(6):438–44. DOI: 10.1007/s11604­006­0053­yKoh D.M., Padhani A.R. Diffusion­weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006;79(944):633–5. DOI: 10.1259/bjr/29739265Connors J.M. State­of­the­art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23(26):6400–8. DOI: 10.1200/JCO.2005.05.016Eissa L., Abdel Razek A.A.K., Helmy E. Arterial spin labeling and diffusion­weighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. Clin Imaging 2021;71:63–8. DOI: 10.1016/j.clinimag.2020.10.057Eraky A.M., Beck R.T., Treffy R.W. et al. Role of advanced MR imaging in diagnosis of neurological malignancies: current status and future perspective. J Integr Neurosci 2023;22(3):73. DOI: 10.31083/j.jin2203073Giraudo C., Simeone R., Fosio M. et al. Diagnostic value of PET/MR with DWI for Burkitt lymphoma. Diagnostics (Basel) 2021;11(10):1867. DOI: 10.3390/diagnostics11101867Hwang S., Panicek D.M. Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol 2007;36(11):1017–27. DOI: 10.1007/s00256­007­0308­4Liu Y., Wang Y., Wang P., Yu Q. A retrospective study to evaluate the CT and MR imaging findings of non­Hodgkin’s lymphoma affecting the jaw bones. Oral Radiol 2022;38(4):509–16. DOI: 10.1007/s11282­021­00582­ySharma S., Leung W.H., Deqing P. et al. Osteonecrosis in children after allogeneic hematopoietic cell transplantation: study of prevalence, risk factors and longitudinal changes using MR imaging. Bone Marrow Transplant 2012;47(8):1067–74. DOI: 10.1038/bmt.2011.234Siegel R.L., Miller K.D., Wagle N.S. et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. DOI: 10.3322/caac.21763Thuy T.T.M., Trang N.T.H., Vy T.T. et al. Role of diffusion­weighted MRI in differentiation between benign and malignant anterior mediastinal masses. Front Oncol 2022;12:985735. DOI: 10.3389/fonc.2022.985735Toledano­Massiah S., Luciani A., Itti E. et al. Whole­body diffusion­weighted imaging in Hodgkin lymphoma and diffuse large B­cell lymphoma. Radiographics 2015;35(3):747–64. DOI: 10.1148/rg.2015140145Winzer R., Hoberück S., Zöphel K. et al. Diffusion-­weighted MRI for initial staging in Hodgkin’s lymphoma: comparison with FDG PET. Eur J Radiol 2020;123:108775. DOI: 10.1016/j.ejrad.2019.108775